Can science prevail against this more turbulent backdrop of the Trump administration? Yahoo Finance executive editor Brian Sozzi talks at length with Novartis ( NVS ) CEO Vas Narasimhan. Narasimhan has led the drug giant since 2018, doing deals that have expanded the company’s pipeline in areas like heart disease and cancer. Still, Narasimhan is feeling pressure to bring the investments to the bottom line to jumpstart its stock price.

In the last year, Novartis shares have declined 6.69%. During that same timespan, the S&P 500 and Dow Jones Industrial Average have gained 22.8% and 12%, respectively. The iShares U.S. Healthcare ETF ( IYH ) is up slightly in the past year. The stock prices of Pfizer ( PFE ) and Moderna ( MRNA ) are down 8.5% and 61%, respectively in the past year.

For full episodes of Opening Bid, listen on your favorite podcast platform or watch on our website.